A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies.

breast cancer, biliary tract carcinoma, ovarian, endometrial cancer, and squamous non-small cell lung cancer.

Incidence of AEs/SAEs, Incidence of DLTs, Changes from baseline in laboratory findings, ECGs and vital signs, Changes in physical examination (including ECOG)

Radiological response evaluated according to RECIST v1.1 - objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS)., Serum concentrations of AZD8205, anti-B7-H4 antibody (INT016) and unconjugated payload (AZ14170132)., Pharmacodynamics (PK) parameters of AZD8205, INT016 and AZ14170132, including but not limited to area under the concentration-time curve (AUC), maximum observed concentration (Cmax), time to reach maximum concentration (tmax), clearance and half-life, as data allow., The number and percentage of participants who develop anti-drug antibody (ADAs)., Additional Sub Study 1 Secondary end points: Changes in tumor cell γH2AX protein expression on treatment., Additional Sub Study 2 Secondary end points: Changes in tumor cell γH2AX protein expression on treatment., Additional Sub Study 2 Secondary end points: Serum concentrations and PK parameters (where applicable) of rilvegostomig; Incidence of ADAs against rilvegostomig in serum, Additional Sub study 4 secondary endopoints: Plasma concentration and PK parameters of AZD9574 Serum concentrations and PK parameter (where applicable) of rilvegostomig The number and percentage of participants who develop ADAs.

No related papers found yet.

Belgium, France, Hungary, Italy, Netherlands, Poland, Spain